NASDAQ : APLS
Apellis Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 41.03 USD (At close: May 13, 2026) · Market cap 5.25B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 5.25B |
| Enterprise Value | 5.32B |
Dates
| Measure | Value |
|---|
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 128.02M |
| Shares Outstanding | 128.02M |
| Shares Change (YoY) | +5.48% |
| Shares Change (QoQ) | +3.76% |
| Owned by Insiders (%) | 3.37% |
| Owned by Institutions (%) | 73.73% |
| Float | 83.22M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 39.98 |
| Forward PE | n/a |
| PS Ratio | 4.75 |
| Forward PS | 5.79 |
| PB Ratio | 12.65 |
| P/TBV Ratio | 12.66 |
| P/FCF Ratio | 140.20 |
| P/OCF Ratio | 139.07 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 39.94 |
| EV / Sales | 4.82 |
| EV / EBITDA | 31.94 |
| EV / EBIT | 32.21 |
| EV / FCF | 142.06 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.63 |
| Quick Ratio | 3.00 |
| Debt / Equity | 1.15 |
| Debt / EBITDA | 2.68 |
| Debt / FCF | 12.70 |
| Interest Coverage | 3.79 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 46.02% |
| Return on Assets (ROA) | 10.93% |
| Return on Invested Capital (ROIC) | 37.84% |
| Return on Capital Employed (ROCE) | 20.68% |
| Weighted Average Cost of Capital (WACC) | 3.40% |
| Revenue Per Employee | $1.50M |
| Profits Per Employee | $180,337 |
| Employee Count | 739 |
| Asset Turnover | 1.17 |
| Inventory Turnover | 3.47 |
Taxes
| Measure | Value |
|---|
| Income Tax | 1.88M |
| Effective Tax Rate | 1.39% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.25 |
| 52-Week Price Change | +134.19% |
| 50-Day Moving Average | 32.36 |
| 200-Day Moving Average | 25.86 |
| Relative Strength Index (RSI) | 84.49 |
| Average Volume (20 Days) | 7,541,234 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 10.75M |
| Short Previous Month | 14.24M |
| Short % of Shares Out | 8.40% |
| Short % of Float | 12.92% |
| Short Ratio (days to cover) | 1.15 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.11B |
| Gross Profit | 710.47M |
| Operating Income | 165.22M |
| Pretax Income | 135.15M |
| Net Income | 133.27M |
| EBITDA | 166.63M |
| EBIT | 165.22M |
| Earnings Per Share (EPS) | $1.03 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 406.20M |
| Total Debt | 475.76M |
| Net Cash | -69.56M |
| Net Cash Per Share | -$0.54 |
| Equity (Book Value) | 414.92M |
| Book Value Per Share | 3.24 |
| Working Capital | 744.57M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 37.77M |
| Capital Expenditures | -305,000 |
| Depreciation & Amortization | 1.40M |
| Net Borrowing | n/a |
| Free Cash Flow | 37.47M |
| FCF Per Share | $0.29 |
Margins
| Measure | Value |
|---|
| Gross Margin | 64.28% |
| Operating Margin | 14.95% |
| Pretax Margin | 12.23% |
| Profit Margin | 12.06% |
| EBITDA Margin | 15.08% |
| EBIT Margin | 14.95% |
| FCF Margin | 3.39% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -5.48% |
| Shareholder Yield | -5.48% |
| Earnings Yield | 2.54% |
| FCF Yield | 0.71% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $35.53 |
| Price Target Difference | -13.40% |
| Analyst Consensus | Hold |
| Analyst Count | 19 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 0.95 |
| Piotroski F-Score | 6 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |